Table 1 Baseline characteristics in overall and according to acute treatment strategy
From: Influence of nocturnal hypoxemia on follow-up course after type B acute aortic syndrome
Characteristics | All patients (n = 103) | Medical therapy only (n = 71) | Aortic stenting (n = 32) | p |
|---|---|---|---|---|
Cardiovascular risk factors | ||||
Age, years | 57.8 (12.1) | 59.6 (11.7) | 53.8 (12.3) | 0.022 |
Male, n (%) | 78 (75.7) | 54 (76.1) | 24 (75.0) | 0.91 |
BMI, kg/m2 | 28.1 (5.5) | 28.8 (5.6) | 26.7 (4.8) | 0.068 |
Abdominal circumferencea, cm | 105.5 (14.3) | 107.8 (13.3) | 100.3 (15.1) | 0.014 |
Current smoking, n (%) | 39 (37.9) | 27 (38.0) | 12 (37.5) | 0.96 |
Diabetes mellitus, n (%) | 14 (13.6) | 12 (16.9) | 2 (6.3) | 0.22 |
Dyslipidemia, n (%) | 46 (44.7) | 37 (52.1) | 9 (28.1) | 0.023 |
Prior cardiovascular disease, n (%) | 20 (19.4) | 15 (21.2) | 5 (15.6) | 0.51 |
Prior aortic surgery, n (%) | 19 (18.4) | 17 (23.9) | 2 (6.3) | 0.032 |
Connective tissue disease, n (%) | 15 (14.6) | 6 (8.5) | 9 (28.1) | 0.014 |
Biological data | ||||
Hemoglobin, g/dl, median (IQR) | 13.6 [11.7–14.4] | 13.5 [11.5–14.4] | 13.9 [12.5 –14.4] | 0.29 |
GFR, ml/mn/1.73 m2 | 77.1 (23.4) | 75.2 (23.2) | 81.4 (23.5) | 0.21 |
LDL cholesterol, g/l, median (IQR) | 0.83 [0.67–1.09] | 0.80 [0.65–1.00] | 0.94 [0.74 –1.15] | 0.055 |
Treatment for hypertension before acute event, n (%) | 83 (80.6) | 59 (83.1) | 24 (75.0) | |
Blood pressure monitoring data, at the time of the scheduled cardiovascular assessment | ||||
24-h SBP, mmHg | 124.1 (14.5) | 123.2 (13.7) | 126.1 (16.1) | 0.35 |
24-h DBP, mmHg | 70.7 (8.0) | 71.1 (7.6) | 69.9 (8.9) | 0.50 |
Nocturnal SBP, mmHg | 120.6 (15.4) | 120.4 (15.1) | 121.1 (16.3) | 0.82 |
Nocturnal DBP, mmHg | 68.0 (8.9) | 68.6 (8.9) | 66.4 (9.1) | 0.25 |
Non-dipping status, n (%) | 83 (80.6) | 58 (81.7) | 25 (78.1) | 0.67 |
Treatment score, number of hypertensive drugs, median (IQR) | 3.0 [3.0–4.0] | 4.0 [3.0 –4.0] | [2.0 -4.0] | 0.044 |